BoironBOIRF 62 Buyback Yield % is 0.01 as of Jul. 03, 2026, which is 75% below its 10-year median of 0.04. GuruFocus rates BOIRF with a GF Score™ of 62/100 and a GF Value™ of $33.44 (Fairly Valued). The stock has 5 warning signs investors should review. Among 292 Drug Manufacturers companies, Boiron ranks better than 67.47% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for Boiron's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOIRF vs ZTS, UTHR, VTRS: Buyback Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Boiron's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Boiron Buyback Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Boiron's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Boiron's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Boiron (BOIRF) has a Buyback Yield % of 0.01 as of Jul. 03, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Boiron and its competitors. This is 75% below median its historical median of 0.04. According to the industry distribution chart, Boiron ranks #95 out of 292 companies in the Drug Manufacturers industry, placing it in the top 32.5%.
Is Boiron's Buyback Yield % too high?
Boiron's current Buyback Yield % of 0.01 is 75% below median its 10-year median of 0.04. Based on the distribution chart, Boiron ranks #95 out of 292 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Boiron has a GF Score™ of 62/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Boiron's Buyback Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Boiron ranks #95 out of 292 companies for Buyback Yield %. This puts Boiron in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Boiron and its competitors. Boiron's current Buyback Yield % is 0.01, which is 75% below median its own 10-year median of 0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Boiron stock overvalued right now?
Based on GuruFocus' analysis, Boiron (BOIRF) is currently considered Fairly Valued. The stock's GF Value™ is $33.44, compared to a current price of $31.90 — trading 4.6% below its estimated fair value. The current Buyback Yield % is 0.01, which is 75% below median its 10-year median of 0.04. Boiron's overall GF Score™ is 62/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Boiron (BOIRF), the current Buyback Yield % is 0.01 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Boiron (BOIRF) Overvalued in 2026?
Based on GuruFocus' analysis, Boiron stock appears to be undervalued.
The current stock price of $31.90 is trading 4.6% below its estimated GF Value™ of $33.44.
GuruFocus considers Boiron to be Fairly Valued.
Key valuation signals for BOIRF:
Buyback Yield %: 0.01 (75% below median its 10-year median of 0.04)
GF Value™: $33.44 vs. price of $31.90 (4.6% below fair value)
No single metric tells the full story. See the BOIRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Boiron SA is a drug manufacturer that focuses on homeopathic products. The company's revenue is roughly split between its nonproprietary homeopathic medicines and products in its over-the-counter specialties category. Boiron's nonproprietary medicines are generic products that do not refer to any therapeutic indication, while the specialties category includes first-resort products provided in tablet form, are bottled to use as drops, syrups, or ointments. Geographical segments are France, Europe, North America, and other countries. It generates a majority of revenue from France. The company's products include Oscillococcinum, Stodal and Stodaline, Arnigel, Camilia, Sedatif PC, Coryzalia, Homeoptic, and Homeovox.
62GF Score
Get the complete analysis for BOIRF
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOIRF has been successfully added to your 
